Personal GrowthLeave a Comment on BYDUREON PACKAGE INSERT PDF


Learn about BYDUREON, a non-insulin treatment option for adults with type 2 diabetes available in the BYDUREON Pen. Find dosing and administration information for BYDUREON, including instructions for use. Learn about BYDUREON® BCise® including efficacy, safety, PK profile, and dosing, and available resources, including Important Safety Information.

Author: Keramar Nagor
Country: Chile
Language: English (Spanish)
Genre: Life
Published (Last): 28 January 2013
Pages: 249
PDF File Size: 16.50 Mb
ePub File Size: 16.37 Mb
ISBN: 725-3-69134-666-9
Downloads: 87311
Price: Free* [*Free Regsitration Required]
Uploader: Bralabar

Fibric acid derivatives may enhance the hypoglycemic effects of antidiabetic agents through increased insulin sensitivity and decreased glucagon secretion. Thus, salicylates can decrease blood glucose concentrations.

PDR Search

Hemodialysis Exenatide is not recommended for use in patients with end-stage renal disease ESRD on continuous or intermittent hemodialysis. Other symptoms, like headache, dizziness, nervousness, mood changes, or hunger are not blunted. Although specific dose recommendations are not ybdureon for most agents, the clinician should consider a dose reduction of the insulin secretagogue or insulin when used in combination with exenatide.

Since promethazine is a phenothiazine antihistamine, it should be used cautiously in patients receiving antidiabetic agents; patients should routinely monitor their blood glucose as indicated.

The Cmax values increased less than proportionally over the inserf range. Major The manufacturer of insulin detemir packwge initiating therapy with insulin detemir at 10 units subcutaneously once daily when combining with a GLP-1 receptor agonist such as exenatide. Replace the blue cap after injection.

Bydureon (exenatide) dose, indications, adverse effects, interactions from

Moderate Green tea catechins have been shown to decrease serum glucose concentrations in vitro. Changes in glucose tolerance occur more commonly in patients receiving 50 mcg or more of ethinyl estradiol or equivalent per day in combined oral contraceptives COCswhich are not commonly used in practice since the marketing of lower dose COCs, patches, injections and rings. Hypoglycemia has occurred during fluoxetine therapy. Initially, 5 mcg subcutaneously twice daily given within the minute period before the morning and evening meal.

Furthermore, tacrolimus has been implicated in isnert insulin-dependent diabetes mellitus in patients after renal transplantation. Moderate Salicylates, by inhibiting prostaglandin E2 synthesis, can indirectly increase insulin secretion. Early warning signs of hypoglycemia may be less obvious in patients with hypoglycemia unawareness which can be due to a long history of diabetes where deficiencies in the release or response to counter regulatory hormones existwith autonomic neuropathy, intensified diabetes control, or taking beta-blockers, guanethidine, or reserpine.


Insulin secretion subsides as ineert occurs.

Decreased insulin production may occur in the pancreas due to a direct effect on pancreatic beta cells. This interference can lead to a loss of diabetic control, so diabetic patients should be monitored closely if these drugs are initiated. Patients receiving these drugs concomitantly should be monitored for changes in glycemic control.

Do NOT mix exenatide with insulin. The cessation of tobacco smoking may result in a decrease in blood glucose.

Fever, thyroid disease, infection, recent trauma or surgery, diarrhea secondary to malabsorption, vomiting, and certain medications can affect requirements of antidiabetic agents; dosage adjustments may be necessary. Consideration should be given to alternative antidiabetic therapy in patients with a history of pancreatitis. Drospirenone; Ethinyl Estradiol; Levomefolate: Although routine monitoring of serum calcitonin is of uncertain value in patients treated with extended-release exenatide, if serum calcitonin is measured and found to be elevated, the patient should be referred to an endocrinologist for further evaluation.

When added to insulin detemir, a reduction in the dose of insulin detemir may be needed to reduce hypoglycemia; the insulin detemir package label recommends a dose of insulin detemir 10 units subcutaneously once daily when combining with a GLP-1 receptor agonist.

Some beta-blockers, particularly non-selective beta-blockers such as propranolol, have been noted to potentiate insulin-induced hypoglycemia and a delay in recovery of blood glucose to normal levels. Minor Tobacco smoking is known to aggravate insulin resistance.

Endogenous human incretins, such as glucagon-like peptide-1 GLP-1 enhance insulin secretion after release from the gut into the systemic circulation. Overall steady state AUC of digoxin was not altered. Exenatide restores first-phase insulin response to an IV bolus of glucose. Aspiration is not necessary. If a patient develops hypoglycemia during treatment, adjust anti-diabetic drug regimen accordingly.

Moderate Sympathomimetic agents and adrenergic agonists tend to increase blood glucose concentrations when administered systemically. Although specific dose recommendations are not available, a lower dose of the insulin may be required to reduce the risk of hypoglycemia in this setting.


If a dose is missed and the next regularly scheduled dose is 1 or 2 days later, the patient should not administer the missed dose, instead they should wait until the next regularly scheduled dose. Moderate In patients with diabetes mellitus, fluoxetine may alter glycemic control. Minor Carbonic anhydrase inhibitors may alter blood sugar. According to OBRA, the use of antidiabetic medications should include monitoring e.

The drug is not indicated in infants or neonates. In large doses, salicylates uncouple oxidative phosphorylation, deplete hepatic and muscle glycogen, and cause hyperglycemia and glycosuria. Moderate The concomitant use of clarithromycin and antidiabetic agents can result in significant hypoglycemia. Patients should also self-monitor blood glucose levels.

Corticosteroids stimulate hepatic glucose production and inhibit peripheral glucose uptake into muscle and fatty tissues, producing insulin resistance. Monitor patients on antidiabetic agents for worsening glycemic control. Occupation of the GLP-1 receptor site by exenatide results in an increase in both glucose-dependent synthesis of insulin, and in vivo secretion of insulin from pancreatic beta cells in the presence of elevated glucose.

Because of this, a potential pharmacodynamic interaction exists between thiazide diuretics and antidiabetic agents. Monitor blood glucose and glycemic control and adjust therapy as clinically indicated.

Minor Increased frequency of blood glucose monitoring may be required when clonidine is given with antidiabetic agents. When the autoinjector is removed from the skin, the green shield will move back up to lock over the needle. See the manufacturer’s instructions for use for complete administration directions and illustrations. Moderate A potential pharmacodynamic interaction exists between indapamide and antidiabetic agents, like incretin mimetics.

Tobacco smoking is known to aggravate insulin resistance. A Byetta Pen can be used for up to 30 days after first use. Moderate Patients receiving antidiabetic agents should use dietary supplements of Garlic, Allium sativum with caution. This should be taken into consideration in patients with impaired glucose tolerance or diabetes mellitus who are receiving antidiabetic agents.